AIP
COGT icon

Arrowpoint Investment Partners’s Cogent Biosciences COGT Stock Holding History

Arrowpoint Investment Partners’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$375K Sell
9,698
-4,086
-30% -$143K 0.08% 81
2026
Q1 		$531K Buy
13,784
+6,431
+87% +$237K 0.47% 40
2025
Q4 		$261K Sell
7,353
-8,745
-54% -$246K 0.04% 91
2025
Q3 		$231K Buy
+16,098
New +$191K 0.23% 61

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Arrowpoint Investment Partners's COGT Position: Q2 2026 in Review

Arrowpoint Investment Partners reduced its Cogent Biosciences (COGT) stake by 30% in Q2 2026, selling an estimated $143K and leaving 9,698 shares worth $375K. The position accounts for 0.08% of the portfolio, ranked #81.

Arrowpoint Investment Partners first reported a position in COGT in Q3 2025 and has held it in 4 quarters since. The position peaked at $531K in Q1 2026. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Arrowpoint Investment Partners held 9,698 shares of Cogent Biosciences worth $375K as of Q2 2026.
  • Arrowpoint Investment Partners sold 4,086 Cogent Biosciences shares in Q2 2026, an estimated $143K.
  • Cogent Biosciences made up 0.08% of Arrowpoint Investment Partners's portfolio in Q2 2026, its #81 holding.
  • Arrowpoint Investment Partners first reported a position in Cogent Biosciences in Q3 2025 and has held it in 4 quarters since.
  • Arrowpoint Investment Partners's Cogent Biosciences position peaked at $531K in Q1 2026.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.